Three Probable Pediatrics COVID-19 Cases with Kawasaki-Like Disease: A Case Series with Fallow-Up

Sedigheh Rafiei Tabatabaei¹, Abdollah Karimi ¹, Hamid Rahimi², Shahnaz Armin¹, Seyed Alireza Fahimzad¹, Roxana Mansour Ghanaie¹, Bahar Dehghan³, Maryam Kazemiaghdam⁴, Marzieh Alinezhad⁵, Rana Saleh², Shima Saeidi², Narges Sharifi², Davood Ramezani Nezhad³, Mina Alibeik¹ and Zahra Pourmoghaddas^{2,*}

¹Pediatric Infections Research Center, Research Institute for Children Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Pediatric Infectious Disease Department, Isfahan University of Medical Sciences, Isfahan, Iran

³Pediatric Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan, Iran

⁴Pediatric Pathology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁵Department of Radiology, Isfahan University of Medical Sciences, Isfahan, Iran

*Corresponding author: Pediatric Infectious Disease Department, Isfahan University of Medical Sciences, Isfahan, Iran. Email: zahrapormoghaddas@yahoo.com

Received 2020 May 11; Revised 2020 November 01; Accepted 2020 November 14.

Abstract

The first case of Kawasaki-like disease in children infected with COVID-19 was reported in a preprint case report. In the present case series, three pediatric probable cases with COVID-19, who presented signs and symptoms of Kawasaki-like syndrome, and their three-month follow-up are provided.

Keywords: COVID-19, Kawasaki Disease, Child, Comorbidity

1. Introduction

The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes severe acute respiratory syndrome, was first identified at the end of 2019 (1). Initially, there was no evidence about coronavirus disease 2019 (COVID-19) infection in pediatrics (2). However, over time, children infected with COVID-19 were reported in various areas (3, 4).

According to the European Centre for Disease Prevention and Control (ECDC) and (5) Iranian Pediatric Association statement (6), a probable COVID-19 case is a patient with signs and symptoms of COVID-19 plus chest imaging is in accordance with COVID-19; however, the result of polymerase chain reaction (PCR) is inconclusive.

In April 2020, the World health organization (WHO) announced new criteria for diagnosing an illness that was observed among pediatric cases with COVID-19, named the Multisystem inflammatory syndrome in children (MIS-C). Some children with MIS-C have the signs and symptoms of complete or incomplete Kawasaki disease.

In the present study, we reported three pediatrics cases with the signs and symptoms of Kawasaki and their three-month follow-up.

2. Case Presentation

2.1. Case 1

An 11-years-old boy with a history of fever and diarrhea lasting for six days was admitted to the pediatric COVID-19 center. On admission, he was suffering from coughing and fever. Physical examination revealed tachypnea (36 times per minute) and low oxygen saturation (91% in room air). Laboratory tests showed lymphopenia and high C-reactive protein (CRP).

Based on the chest CT scan (Table 1 and Figure 1) as well as history and physical examination, he was triaged as a probable COVID-19 case. Therefore, following the Iranian Pediatric Association statement, he was treated with hydroxychloroquine and Lopinavir/Retinavir (5). On the second day of admission, physical examination showed non-purulent bilateral conjunctivitis, maculopapular rashes on the trunk, red strawberry tongue, and severe nonpitting edema on his feet (Figure 2). Considering lab data and the presented signs, the patient was diagnosed with complete Kawasaki, and intravenous immunoglobulin (IVIG) and high-dose aspirin (ASA) were administered (7).

The echocardiography for the first time showed mild mitral and tricuspid regurgitation plus pericardial effu-

Table 1. Physical Examinations, Laboratory Data, and Imaging Study of the Studied Cases

Findings	Case 1	Case 2	Case 3
Age	11 years old	9 months old	14 months old
Sex	Male	Female	Female
Physicalexamination			
PR	100	110	110
RR	36	40	45
O2sat	91%	95%	94%
T	38c	38.7	38.9
CRT	< 2 second	< 2 second	< 2 second
AVPU	A	A	A
Ability to drink	Good	Good	Good
Labdata			
Lymphocyte (%)	7.8	6, 25	17.3
Hb	12	11, 9.4	9.7
PLT	173000	592000, 521000	599000
AST	49	56, 137	83
ALT	18	37, 184	55
Alb	2.8	3, 3	3.5
Na	123	134, 132	126
CRP	23	183, 97	50
ESR	64	55, 46	66
U/A(WBC)	5	0, 0	0
Echocardiography	Minimal MR, TR, pericardial effusion	Mild MR, TR, PI	Normal
Imaging			
One side involvement	-	-	-
Two side involvement	+	+	+
Ground glass opacity	+	+	+
Subpleural opacity	+	+	+
Consolidation	-	-	-
Hallo sign/ Reverse hallo sign	-	-	-
Micro nodules	-	-	-
Crazy patching	-	-	-

Abbreviations: PR: pulse rate, RR: respiratory rate, BP: blood pressure, O2 sat: oxygen saturation CRT: capillary refill time, AVPU: a scale for recording the patient's level of consciousness, WBC: white Blood cells, PLT: platelet, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, Alb: albumin, ESR: erythrocyte sedimentation, CRP: C-reactive protein, U/A: urine analysis, MR: mitral regurgitation, TR: tricuspid regurgitation, PI: pulmonary regurgitation

sion. Seven days later, the echocardiography revealed right atrium and ventricle enlargement with good ejection fraction. Although our patient was admitted before April, according to the currently available guidelines, it can be said that he had MIS-C, mainly because of diarrhea, skin manifestations, and cardiac involvement with the presentation of typical Kawasaki. On follow-up examinations, the peeling was considerable (Figure 2) on the 10th day of ill-

nesses. On the 15th day, the left coronary artery (LCA) ectasia was seen and the enlargement of the right side was the same as the 7th day. Low-dose ASA was continued until the third month after the admission until echocardiography became normal. After two months, the COVID-19 IgG titer was 1.8 with an index > 1.

Figure 1. Chest CT scan of Case 1

2.2. Case 2

A 9-months-old girl presented to the pediatric COVID-19 center with a complaint of two days of fever and cough. Her mother was among the health staff of the center. The mother had a fever and cough one week ago. Her physical examination showed fever (38.2) and tachypnea (40 times per minute). Leukocytosis with lymphopenia, normochromic normocytic anemia, high level of CRP, and erythrocyte sedimentation rate (ESR) were detected in the lab study (Table 1). According to signs, symptoms, and chest CT scan, she was a probable COVID-19 case (Figure 3), (6). Therefore, she was treated with hydroxychloroquine (6).

On the 3rd day of her illness, nonpurulent bilateral conjunctivitis plus maculopapular rushes were the main signs observed on physical examination. On the 4th day of fever, because of previous signs, echocardiography was performed, and lab tests were repeated. Moderate mitral regurgitation, tricuspid, and pulmonary regurgitation were the echocardiography findings. She was treated with IVIG and high-dose ASA as a case of incomplete Kawasaki (7). According to new data, she was also a case of MIS-C with a presentation of atypical Kawasaki because of skin and cardiac manifestation. On the follow-up examination, echocardiography revealed LCA ectasia on the 15th day of follow-up, and on the 30th day, the right heart size was enlarged. After three months, the ectasia was improved, but the enlargement was persistent, and low ASA was continued. The parents of the child did not allow us to check the COVID-19 IgM and IgG antibodies.

2.3. Case 3

A 14-months-old boy presented with a history of five days of fever and rhinorrhea. The physical examination revealed tachypnea (45 times per minute), normal oxygen saturation in the air room (93%), bilateral nonpurulent conjunctivitis, maculopapular rashes in his feet and

hands, strawberry tongue, and edema of hands and feet. The laboratory tests showed Lymphopenia, high levels of CRP, ESR, and alanine aminotransferase (ALT) (Table 1). Hence, he was treated as a probable case of COVID-19 similar to Kawasaki disease (Figure 4), (7) with high-dose ASA and IVIG. Nevertheless, the echocardiography was normal. The patient was discharged after six days with a good health condition. Unfortunately, when we called them for follow-up a week later, the parents told us he died three days after discharge at home.

3. Discussion

COVID-19 is a pandemic disease caused by the novel coronavirus, named SARS-CoV-2. The sensitivity of PCR is not high (8). The Iranian Pediatric Infectious Diseases Society, in its statement on COVID-19 management, defined a probable COVID-19 case as follows: when laboratory and imaging findings are in accordance with COVID-19 but the nasopharyngeal PCR for SARS-CoV-2 is negative. The exact cause of Kawasaki disease is not clear yet, and further studies are needed.

Infection agents, such as retroviruses and parvovirus B19, can cause Kawasaki disease (9, 10). In 2005, Esper et al., in a case-control study, reported an association between coronaviruses and Kawasaki disease (11). The acute onset of Kawasaki disease and its wavelike spread reported in winter can indicate the Kawasaki disease caused by infectious diseases (12).

Another study has mentioned the expansion of CD8 lymphocytes as one of the pathogenesises of Kawasaki due to infectious diseases (13). It has been demonstrated that patients infected with COVID-19 have lower levels of CD8 lymphocyte (14); however, the exact cause is not clear, and further studies are needed. Some studies have reported that SARS-CoV-2 can cause capillary inflammation and endothelial dysfunction in many organs, such as kidney and skin (15). Therefore, the manifestation of Kawasaki disease may be due to this capillary inflammation. After time passed from April 2020, some studies have been conducted on the pathophysiology of SARS-CoV-2 and MIS-C and Kawasaki features of this syndrome. Children with a special genetic variant in regulatory T and B cells, which destroys the immune complex, have a higher chance of suffering from MIS-C with Kawasaki features (16).

Apart from the pathophysiology of this syndrome, the effect of this inflammatory process in different organs is important. In the introduced cases, two of three patients reported normal heart function after three months. Case 3 died. Thus, follow-up of the patient's organs function, especially cardiac follow-up after discharge, is suggested.

Figure 2. Strawberry Tongue , Plantar Edema, and maculopapular Rashes, and peeling in case 1

Figure 3. Chest CT scan of case 2

Figure 4. Chest Ct Scan of case 3

Recording the data of these patients is helpful to understand the long-term follow-up effect of this inflammatory process in different organs of children and indicate the times of different organ evaluation by the physician in pediatric patients with MIS-C.

Footnotes

Authors' Contribution: All authors were involved in data gathering, writing the first draft, and the review of the draft.

Conflict of Interests: The authors declared no conflict of interest.

Ethical Approval: Isfahan University of Medical Sciences Ethics Committee approved this case report.

Funding/Support: None declared.

Informed Consent: All parents signed the consent and in the consent, it was mentioned that the faces and the names of their children are kept confidential.

References

1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents*. 2020;**55**(3):105924. doi: [10.1016/j.ijantimicag.2020.105924](https://doi.org/10.1016/j.ijantimicag.2020.105924). [PubMed: [32081636](https://pubmed.ncbi.nlm.nih.gov/32081636/)]. [PubMed Central: [PMC7127800](https://pubmed.ncbi.nlm.nih.gov/PMC7127800/)].
2. Seyedi SJ, Shojaeian R, Hiradfar M, Mohammadipour A, Alamdaran SA. Coronavirus Disease 2019 (COVID-19) Outbreak in Pediatrics and the Role of Pediatricians: A Systematic Review. *Iranian Journal of Pediatrics*. 2020;**30**(2). doi: [10.5812/ijp.102784](https://doi.org/10.5812/ijp.102784).
3. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. *N Engl J Med*. 2020;**382**(17):1663-5. doi: [10.1056/NEJMc2005073](https://doi.org/10.1056/NEJMc2005073). [PubMed: [32187458](https://pubmed.ncbi.nlm.nih.gov/32187458/)]. [PubMed Central: [PMC7121177](https://pubmed.ncbi.nlm.nih.gov/PMC7121177/)].
4. Tagarro A, Epalza C, Santos M, Sanz-Santaefemia FJ, Otheo E, Moraleda C, et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. *JAMA pediatrics*. 2020.

5. *case definition and european surveillance human infection novel coronavirus-2019*. 2019. Available from: <https://www.ecdc.europa.eu/en/case-definition-and-european-surveillance-human-infection-novel-coronavirus-2019-ncov>.
6. Karimi A, Rafiei Tabatabaei S, Rajabnejad M, Pourmoghaddas Z, Rahimi H, Armin S, et al. An Algorithmic Approach to Diagnosis and Treatment of Coronavirus Disease 2019 (COVID-19) in Children: Iranian Expert's Consensus Statement. *Archives of Pediatric Infectious Diseases*. 2020;**8**(2). doi: [10.5812/pedinfec.102400](https://doi.org/10.5812/pedinfec.102400).
7. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. *Circulation*. 2017;**135**(17):e927–99. doi: [10.1161/CIR.0000000000000484](https://doi.org/10.1161/CIR.0000000000000484). [PubMed: [28356445](https://pubmed.ncbi.nlm.nih.gov/28356445/)].
8. Kim H, Hong H, Yoon SH. Diagnostic Performance of CT and Reverse Transcriptase Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis. *Radiology*. 2020;**296**(3):E145–55. doi: [10.1148/radiol.2020201343](https://doi.org/10.1148/radiol.2020201343). [PubMed: [32301646](https://pubmed.ncbi.nlm.nih.gov/32301646/)]. [PubMed Central: [PMC7233409](https://pubmed.ncbi.nlm.nih.gov/PMC7233409/)].
9. Burns JC, Geha RS, Schneeberger EE, Newburger JW, Rosen FS, Glezen LS, et al. Polymerase activity in lymphocyte culture supernatants from patients with Kawasaki disease. *Nature*. 1986;**323**(6091):814–6. doi: [10.1038/323814a0](https://doi.org/10.1038/323814a0). [PubMed: [2430187](https://pubmed.ncbi.nlm.nih.gov/2430187/)].
10. Nigro G, Krzysztofciak A, Porcaro MA, Mango T, Zerbini M, Gentilomi G, et al. Active or recent parvovirus B19 infection in children with Kawasaki disease. *The Lancet*. 1994;**343**(8908):1260–1. doi: [10.1016/S0140-6736\(94\)92154-7](https://doi.org/10.1016/S0140-6736(94)92154-7).
11. Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. *J Infect Dis*. 2005;**191**(4):499–502. doi: [10.1086/428291](https://doi.org/10.1086/428291). [PubMed: [15655771](https://pubmed.ncbi.nlm.nih.gov/15655771/)]. [PubMed Central: [PMC7199489](https://pubmed.ncbi.nlm.nih.gov/PMC7199489/)].
12. Yanagawa H, Nakamura Y, Kawasaki T, Shigematsu I. Nationwide Epidemic of Kawasaki Disease in Japan during Winter of 1985–86. *The Lancet*. 1986;**328**(8516):1138–9. doi: [10.1016/S0140-6736\(86\)90541-6](https://doi.org/10.1016/S0140-6736(86)90541-6).
13. Choi IH, Chwae YJ, Shim WS, Kim DS, Kwon DH, Kim JD, et al. Clonal expansion of CD8+ T cells in Kawasaki disease. *J Immunol*. 1997;**159**(1):481–6. [PubMed: [9200489](https://pubmed.ncbi.nlm.nih.gov/9200489/)].
14. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol Immunol*. 2020;**17**(5):533–5. doi: [10.1038/s41423-020-0402-2](https://doi.org/10.1038/s41423-020-0402-2). [PubMed: [32203188](https://pubmed.ncbi.nlm.nih.gov/32203188/)]. [PubMed Central: [PMC7091858](https://pubmed.ncbi.nlm.nih.gov/PMC7091858/)].
15. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. *The Lancet*. 2020;**395**(10234):1417–8. doi: [10.1016/S0140-6736\(20\)30937-5](https://doi.org/10.1016/S0140-6736(20)30937-5).
16. Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. *JCI Insight*. 2019;**4**(4). doi: [10.1172/jci.insight.123158](https://doi.org/10.1172/jci.insight.123158). [PubMed: [30830861](https://pubmed.ncbi.nlm.nih.gov/30830861/)]. [PubMed Central: [PMC6478436](https://pubmed.ncbi.nlm.nih.gov/PMC6478436/)].